Capital Research Global Investors
WST icon

Capital Research Global Investors’s West Pharmaceutical WST Stock Holding History

Capital Research Global Investors’s Portfolio WST Stock Details WST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$151M Buy
+604,011
New +$150M 0.02% 273
2025
Q2 		– Sell
-390,678
Closed -$87.5M – 477
2025
Q1 		$87.5M Buy
390,678
+167,468
+75% +$46.2M 0.02% 298
2024
Q4 		$73.1M Buy
223,210
+63,017
+39% +$19.8M 0.02% 331
2024
Q3 		$48.1M Buy
+160,193
New +$49.1M 0.01% 343
2022
Q4 		– Sell
-494,732
Closed -$122M – 459
2022
Q3 		$122M Buy
494,732
+97
+0% +$29.6K 0.04% 245
2022
Q2 		$150M Buy
494,635
+155
+0% +$50.4K 0.05% 244
2022
Q1 		$203M Sell
494,480
-110,279
-18% -$43.2M 0.05% 237
2021
Q4 		$284M Sell
604,759
-56,636
-9% -$24.4M 0.06% 218
2021
Q3 		$281M Sell
661,395
-264
-0% -$111K 0.07% 217
2021
Q2 		$238M Buy
661,659
+802
+0.1% +$265K 0.06% 230
2021
Q1 		$186M Sell
660,857
-70,282
-10% -$20.1M 0.05% 253
2020
Q4 		$207M Sell
731,139
-149,910
-17% -$42.1M 0.05% 244
2020
Q3 		$242M Sell
881,049
-126,170
-13% -$33.4M 0.07% 198
2020
Q2 		$229M Sell
1,007,219
-290,319
-22% -$57M 0.07% 198
2020
Q1 		$198M Sell
1,297,538
-140,591
-10% -$21.6M 0.08% 189
2019
Q4 		$216M Buy
1,438,129
+1,216
+0.1% +$177K 0.06% 207
2019
Q3 		$204M Buy
1,436,913
+79
+0% +$10.9K 0.07% 206
2019
Q2 		$180M Buy
1,436,834
+967
+0.1% +$114K 0.06% 215
2019
Q1 		$158M Buy
1,435,867
+534,749
+59% +$55.6M 0.05% 228
2018
Q4 		$88.3M Buy
+901,118
New +$97.8M 0.03% 270

Other funds holding WST

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
GIM
Generation Investment Management London, United Kingdom $11.2B AUM 0.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors's WST Position: Q1 2026 in Review

Capital Research Global Investors opened a new position in West Pharmaceutical (WST) in Q1 2026: 604,011 shares worth $151M. The stake represents 0.02% of the portfolio and ranks #273 among its holdings. This is a return to the name: Capital Research Global Investors previously reported a position in WST as recently as Q1 2025.

Capital Research Global Investors first reported a position in WST in Q4 2018 and has held it in 20 quarters since. The position peaked at $284M in Q4 2021. 753 funds tracked by Wall St. Rank hold WST as of Q1 2026.

  • Capital Research Global Investors held 604,011 shares of West Pharmaceutical worth $151M as of Q1 2026.
  • West Pharmaceutical was a new Capital Research Global Investors position in Q1 2026.
  • West Pharmaceutical made up 0.02% of Capital Research Global Investors's portfolio in Q1 2026, its #273 holding.
  • Capital Research Global Investors first reported a position in West Pharmaceutical in Q4 2018 and has held it in 20 quarters since.
  • Capital Research Global Investors's West Pharmaceutical position peaked at $284M in Q4 2021.
  • 753 funds tracked by Wall St. Rank held West Pharmaceutical as of Q1 2026.

Based on Capital Research Global Investors's 13F filing for Q1 2026, filed 13 May 2026.